[{"id":"5d7622ad-719f-47cd-90a0-999fd39d85cf","acronym":"FLYSYN-101","url":"https://clinicaltrials.gov/study/NCT02789254","created_at":"2021-01-18T13:41:02.192Z","updated_at":"2024-07-02T16:35:24.982Z","phase":"Phase 1/2","brief_title":"FLYSYN in MRD Positive AML","source_id_and_acronym":"NCT02789254 - FLYSYN-101","lead_sponsor":"Synimmune GmbH","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 wild-type • FLT3 expression","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 wild-type • FLT3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VX-A901"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/07/2017","start_date":" 02/07/2017","primary_txt":" Primary completion: 09/27/2021","primary_completion_date":" 09/27/2021","study_txt":" Completion: 09/27/2021","study_completion_date":" 09/27/2021","last_update_posted":"2023-12-28"},{"id":"edeab902-2100-4815-8330-db8677913ca6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05266950","created_at":"2022-03-04T15:53:28.701Z","updated_at":"2024-07-02T16:35:52.306Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05266950","lead_sponsor":"Beijing Boren Hospital","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 expression","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CI-135 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-03-27"},{"id":"083867de-5a50-4a67-ac63-c11e42dc2513","acronym":"","url":"https://clinicaltrials.gov/study/NCT05432401","created_at":"2022-06-27T14:54:11.243Z","updated_at":"2024-07-02T16:36:08.274Z","phase":"Phase 1","brief_title":"TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05432401","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" FLT3 • IL6","pipe":" | ","alterations":" FLT3 expression • FLT3 positive","tags":["FLT3 • IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 expression • FLT3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAA05"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 06/09/2023","primary_completion_date":" 06/09/2023","study_txt":" Completion: 06/09/2025","study_completion_date":" 06/09/2025","last_update_posted":"2022-06-27"},{"id":"449f97aa-36f9-4e3c-b3e9-6a9633ccaea5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05383014","created_at":"2022-05-19T11:56:24.419Z","updated_at":"2024-07-02T16:36:10.171Z","phase":"","brief_title":"FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.","source_id_and_acronym":"NCT05383014","lead_sponsor":"Assiut University","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 expression • FLT3 positive","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 expression • FLT3 positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-05-19"}]